|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF1C |
Gene summary for KIF1C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF1C | Gene ID | 10749 |
| Gene name | kinesin family member 1C | |
| Gene Alias | LTXS1 | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O43896 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10749 | KIF1C | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.06e-07 | 2.79e-01 | 0.0155 |
| 10749 | KIF1C | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.85e-33 | 1.12e+00 | -0.1808 |
| 10749 | KIF1C | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.30e-16 | 8.67e-01 | -0.0811 |
| 10749 | KIF1C | HTA11_78_2000001011 | Human | Colorectum | AD | 9.33e-09 | 4.57e-01 | -0.1088 |
| 10749 | KIF1C | HTA11_347_2000001011 | Human | Colorectum | AD | 1.75e-33 | 9.36e-01 | -0.1954 |
| 10749 | KIF1C | HTA11_411_2000001011 | Human | Colorectum | SER | 2.93e-10 | 1.39e+00 | -0.2602 |
| 10749 | KIF1C | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.36e-09 | 1.26e+00 | -0.2196 |
| 10749 | KIF1C | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.34e-08 | 6.91e-01 | -0.1207 |
| 10749 | KIF1C | HTA11_83_2000001011 | Human | Colorectum | SER | 7.44e-15 | 9.60e-01 | -0.1526 |
| 10749 | KIF1C | HTA11_696_2000001011 | Human | Colorectum | AD | 5.95e-31 | 8.94e-01 | -0.1464 |
| 10749 | KIF1C | HTA11_866_2000001011 | Human | Colorectum | AD | 1.43e-22 | 6.78e-01 | -0.1001 |
| 10749 | KIF1C | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.15e-21 | 9.30e-01 | -0.059 |
| 10749 | KIF1C | HTA11_2992_2000001011 | Human | Colorectum | SER | 7.15e-06 | 8.47e-01 | -0.1706 |
| 10749 | KIF1C | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.00e-16 | 1.05e+00 | -0.2061 |
| 10749 | KIF1C | HTA11_546_2000001011 | Human | Colorectum | AD | 1.84e-02 | 4.84e-01 | -0.0842 |
| 10749 | KIF1C | HTA11_866_3004761011 | Human | Colorectum | AD | 4.21e-09 | 4.22e-01 | 0.096 |
| 10749 | KIF1C | HTA11_7663_2000001011 | Human | Colorectum | SER | 5.55e-03 | 6.76e-01 | 0.0131 |
| 10749 | KIF1C | HTA11_10623_2000001011 | Human | Colorectum | AD | 4.68e-06 | 7.45e-01 | -0.0177 |
| 10749 | KIF1C | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.54e-20 | 6.46e-01 | 0.0674 |
| 10749 | KIF1C | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.40e-02 | 5.05e-01 | 0.0112 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
| GO:00164829 | Oral cavity | OSCC | cytosolic transport | 106/7305 | 168/18723 | 2.08e-10 | 5.90e-09 | 106 |
| GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
| GO:000689010 | Oral cavity | OSCC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 40/7305 | 52/18723 | 2.86e-08 | 5.50e-07 | 40 |
| GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
| GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
| GO:00109706 | Oral cavity | OSCC | transport along microtubule | 88/7305 | 155/18723 | 5.35e-06 | 6.02e-05 | 88 |
| GO:00723845 | Oral cavity | OSCC | organelle transport along microtubule | 53/7305 | 85/18723 | 1.10e-05 | 1.14e-04 | 53 |
| GO:00080889 | Oral cavity | OSCC | axo-dendritic transport | 46/7305 | 75/18723 | 7.44e-05 | 5.81e-04 | 46 |
| GO:00989303 | Oral cavity | OSCC | axonal transport | 39/7305 | 64/18723 | 3.12e-04 | 1.94e-03 | 39 |
| GO:00991113 | Oral cavity | OSCC | microtubule-based transport | 96/7305 | 190/18723 | 7.92e-04 | 4.27e-03 | 96 |
| GO:00995184 | Oral cavity | OSCC | vesicle cytoskeletal trafficking | 41/7305 | 73/18723 | 2.18e-03 | 9.95e-03 | 41 |
| GO:00080891 | Oral cavity | OSCC | anterograde axonal transport | 29/7305 | 50/18723 | 5.01e-03 | 1.96e-02 | 29 |
| GO:00474961 | Oral cavity | OSCC | vesicle transport along microtubule | 27/7305 | 47/18723 | 7.93e-03 | 2.90e-02 | 27 |
| GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
| GO:005165615 | Oral cavity | LP | establishment of organelle localization | 147/4623 | 390/18723 | 6.01e-09 | 2.46e-07 | 147 |
| GO:000689015 | Oral cavity | LP | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 29/4623 | 52/18723 | 1.60e-06 | 3.79e-05 | 29 |
| GO:001648214 | Oral cavity | LP | cytosolic transport | 69/4623 | 168/18723 | 2.03e-06 | 4.65e-05 | 69 |
| GO:005165015 | Oral cavity | LP | establishment of vesicle localization | 64/4623 | 161/18723 | 1.65e-05 | 2.86e-04 | 64 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF1C | SNV | Missense_Mutation | rs780072767 | c.2314N>C | p.Glu772Gln | p.E772Q | O43896 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.968) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KIF1C | SNV | Missense_Mutation | c.483N>C | p.Lys161Asn | p.K161N | O43896 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KIF1C | SNV | Missense_Mutation | c.429N>T | p.Glu143Asp | p.E143D | O43896 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KIF1C | SNV | Missense_Mutation | novel | c.1141N>A | p.Gly381Arg | p.G381R | O43896 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIF1C | SNV | Missense_Mutation | c.784N>A | p.Gly262Ser | p.G262S | O43896 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| KIF1C | SNV | Missense_Mutation | novel | c.1210N>T | p.Val404Leu | p.V404L | O43896 | protein_coding | tolerated(0.6) | benign(0) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KIF1C | SNV | Missense_Mutation | c.2508N>A | p.His836Gln | p.H836Q | O43896 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.636) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| KIF1C | SNV | Missense_Mutation | rs201887996 | c.3122G>A | p.Arg1041Gln | p.R1041Q | O43896 | protein_coding | tolerated_low_confidence(0.27) | benign(0.003) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIF1C | insertion | Frame_Shift_Ins | novel | c.1108_1109insACCTTTGTTGTACATTTGAAAAGTTCTTACAGTTTTGTCAAGT | p.Val370AspfsTer65 | p.V370Dfs*65 | O43896 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| KIF1C | SNV | Missense_Mutation | novel | c.1684N>T | p.Pro562Ser | p.P562S | O43896 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |